secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001437749-25-000927
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical prelim Q4 rev $14.1-14.3M; Advanced Energy up >25% QoQ
-------------------------------------------------------------------

- Total Q4 revenue $14.1-14.3M, down ~3-4% YoY; Advanced Energy ~$12.0-12.2M (flat YoY).
- Full-year 2024 revenue $48.0-48.2M, down 8% YoY; Advanced Energy down 11% to $38.5-38.7M.
- OEM revenue Q4 $2.1M (-17% YoY); full-year $9.5M (+6% YoY).
- New AYON Body Contouring System expected to launch H2 2025 pending FDA clearance.
- CEO cites doubled U.S. generator unit sales in H2 vs H1 and GLP-1-driven demand for skin treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774925000927/0001437749-25-000927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774925000927/apyx20250110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-000927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer